undamentalytics Newsletter
Sign in

Evolus, Inc. revenue

Evolus, Inc.'s revenue was $297m in fiscal 2025, up 11.6% on the year before. Since fiscal 2019 ($34.9m) it has grown at a compound 42.9% a year. Over the last twelve months it was $316m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue03557100149202266297316
Growth on the year before——+61.9%+76.3%+49.1%+36.0%+31.8%+11.6%—
Gross profit027385690138182197211
Gross margin—77.1%67.6%56.3%60.4%68.1%68.5%66.3%66.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $295M 99.3% ▲ 11.6%
Services $2.2M 0.7% ▲ 12.8%

From Evolus, Inc.'s 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Evolus, Inc. $316m 13.9% 23.4%
Xeris Biopharma Holdings, Inc. $335m 36.3% 35.8%
Harrow, Inc. $276m 21.1% 39.0%
Ironwood Pharmaceuticals Inc $389m 26.2% -3.1%
Aurora Cannabis Inc $232m 11.7% —
Vanda Pharmaceuticals Inc. $229m 8.1% 2.7%

Compare with peers

Head to head: EOLS vs XERSEOLS vs HROWEOLS vs IRWD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Evolus, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evolus, Inc.